# Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects

> **NCT01459250** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** AGO178C

## Key facts

- **NCT ID:** NCT01459250
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2011-08
- **Final completion:** —
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01459250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01459250, "Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01459250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*